RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @DrAnkurSriv: Delighted that @ResearchNBT @NorthBristolNHS contributed to this important COVID-19 study for patients with IBD. #NBTproud…
RT @j0nnymac1: -1st publication from @clarityibd study!! -Great example of collaborative UK research -Answering important #COVID19 question…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: Read the paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @ClaireBewshea "Anti-SARS-CoV-2 antibody resp…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
Amazing effort by the whole team. Huge THANK YOU 🙏🙏🙏to #marianparkinson and #helengardnerthorpe, @rachelnice3 @ExeterIBD , #suziemarriott, @UK_nurseMax @jotaylor1970 for all your continuous hard work.
RT @Gut_BMJ: Read the paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @ClaireBewshea "Anti-SARS-CoV-2 antibody resp…
RT @IBD_FloMD: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab https://t.co/s8IVo7ugSh
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @Gut_BMJ: Read the paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @ClaireBewshea "Anti-SARS-CoV-2 antibody resp…
RT @AshkanRA: 🚨 New data from @clarityibd in @Gut_BMJ : 📌Anti-SARS-CoV-2 antibody responses attenuated in IBD pts treated with infliximab…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
Read the paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @ClaireBewshea "Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab" via https://t.co/wsMTTvjd2N #COVID19 #IBD @charlie_lees @DrPhil
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
Amazing effort from research team and IBD nurses @StGeorgesTrust that contributed to this study @clarityibd @Gut_BMJ
@geteccu @EntrenaEII ojalá nos expliquen pronto en "español para pacientes" lo que significa 😇 Evidentemente inmunosupresor es menor respuesta inmune, pero ¿qué significa? ↘️ efecto de las vacunas? ↗️riesgo de reinfección? Variantes resistentes? Ciencia
RT @j0nnymac1: -1st publication from @clarityibd study!! -Great example of collaborative UK research -Answering important #COVID19 question…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @j0nnymac1: -1st publication from @clarityibd study!! -Great example of collaborative UK research -Answering important #COVID19 question…
-1st publication from @clarityibd study!! -Great example of collaborative UK research -Answering important #COVID19 questions for #IBD pts -Much more to come -Key msg for IBD pts - IFX Vs IBD VEDO shows NO difference in COVID19 infections. -Keep taking IBD
RT @bottomlineibd: How doctors convey this info to #IBD patients will be vital. Keeping us reassured and informed has the potential to make…
RT @IBD_FloMD: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab https://t.co/s8IVo7ugSh
RT @DrPhil_Gu: #COVID19 ab response in IFX vs VDZ treated #IBD pts 📍Similar rates of 🤢 📍⬇️seroprevalence in IFX 📍Seroconversion: IFX 48…
RT @AshkanRA: 🚨 New data from @clarityibd in @Gut_BMJ : 📌Anti-SARS-CoV-2 antibody responses attenuated in IBD pts treated with infliximab…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @ibdnurse: @researchstockp1 we are one of the sites for this study published in @Gut_BMJ ...... very proud @GastroNW https://t.co/Ss65zc…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @UKGastroDr: Pleased that our team at @ResearchKgh contributed to this @FarhadPeerally2
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @clarityibd: **HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential I…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
@researchstockp1 we are one of the sites for this study published in @Gut_BMJ ...... very proud @GastroNW
**HOT NEWS** First CLARITY IBD Data is out. 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿Potential IFX BLUNTED COVID19 response Vs VEDO. #ibdpatients 👇 ✅Stay on IBD medication ✅Immune system is COMPLEX ✅ V. SOON ➕ data on vaccinati
Great work from all involved well done 👏
Delighted that @ResearchNBT @NorthBristolNHS contributed to this important COVID-19 study for patients with IBD. #NBTproud 🦠IBD IFX Vs IBD VEDO shows NO difference in COVID19 infections. 🧿IBD IFX BLUNTED COVID19 response Vs IBD VEDO @clarityibd
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
#COVID19 ab response in IFX vs VDZ treated #IBD pts 📍Similar rates of 🤢 📍⬇️seroprevalence in IFX 📍Seroconversion: IFX 48% v VDZ 83% 📍Seroconversion: IFX+IMM 37% vs IFX mono 60% Will see similar results with the #COVID19Vaccine?? https://t.co/lYQKjhU
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab https://t.co/s8IVo7ugSh
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
I’m immensely grateful for the #IBD COVID research happening, but I am also really upset about the implications of the data. I’m on IFX (mono therapy). This study indicates my vaccine response will not be as effective as hoped. Not surprising but dishearte
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
Very interesting and important research in IBD / COVID-19! Trabalho interessante e importante sobre DII e Covid
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
@guthealthmd What are your thoughts on the findings from this UK study that identifies differences in infliximab vs vedolizumab, and furthermore for those on immunomodulators too? It's going to be a task and a half to stop patients from worrying about this
RT @charlie_lees: The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data…
The first data from @clarityibd are out @Gut_BMJ 6935 IBD patients from 92 UK sites on infliximab or vedolizumab. Data showing attenuated serological responses to SARS-CoV-2 infection with IFX and immunomodulators (aza/mp/mtx). I will update fully soon
RT @bottomlineibd: How doctors convey this info to #IBD patients will be vital. Keeping us reassured and informed has the potential to make…
How doctors convey this info to #IBD patients will be vital. Keeping us reassured and informed has the potential to make a big difference by stemming any fall-out and reducing anxiety. I urge all HCPs to be mindful of this... https://t.co/QJOcvF1tRQ
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
The first important tesults from the Clarity IBD Study shows attenuated antibody response to SARS-CoV-2 in pts treated with IFX compared with Vedolizumab 👇
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @AshkanRA: 🚨 New data from @clarityibd in @Gut_BMJ : 📌Anti-SARS-CoV-2 antibody responses attenuated in IBD pts treated with infliximab…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
Pleased that our team at @ResearchKgh contributed to this @FarhadPeerally2
This is just such important work congratulations to the Exeter team and all collaborators!
🚨 New data from @clarityibd in @Gut_BMJ : 📌Anti-SARS-CoV-2 antibody responses attenuated in IBD pts treated with infliximab 📌Potential blunted response to 💉in IFX treated pts⁉️ ✳️ First data from @ICARUSIBD reassuring, larger series needed soon htt
RT @Gut_BMJ: #GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @C…
#GUTInTheNews #GUTPressRelease - read the important paper by @clarityibd team @tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @ClaireBewshea "Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab" via https://t.co/omM